Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/15508
標題: 口服人類重組干擾素-α對雞隻免疫功能之調控及對傳染性支氣管炎病毒感染之保護效益
Immunoregulation and Protective Efficiency Against Infectious bronchitis virus of Oral Administration Human Recombinant Interferon-α in Chicken
作者: 王惠君
Wang, Hui-Chung
關鍵字: 干擾素
Interferon
雞傳染性支氣管炎病毒
免疫調節
Infectious bronchitis virus
Immunoregulation
出版社: 獸醫病理生物學研究所
引用: 呂榮修、謝快樂、蔡向榮、林地發、李永林。台灣雞傳染性支氣管炎之發生與病毒分離。中華獸醫誌 19:119-129。1993。 周和源。家禽傳染性支氣管炎病毒之序列分析、抗體力價評估技術及病毒定量方法之研究。國立中興大學獸醫微生物學研究所碩士論文。2002。 黃元品、張婉純、王金和。家禽傳染性支氣管炎台灣二型減毒疫苗之評估。台灣獸醫誌 32(2):123-128。2006。 黃萬居。台灣發生之雞傳染性支氣管炎(初步報告)。台灣畜獸會學報 1:1-5。1958。 游能凱。口服低劑量干擾素對於豬隻免疫功能之調控及對PRRSV與PCV2混合感染之保護效益。國立中興大學獸醫病理學研究所碩士論文。2010。 楊韻蓉。口腔黏膜低劑量干擾素對豬免疫功能之調控及對PRRSV或PRRSV/PCV2 混合感染之保護效益評估。國立中興大學獸醫病理生物學研究所碩士論文。2011。 Adolf G. R. Structure and effects of interferon-gamma. Oncology 42 Suppl 1: 33-40, 1985. Akiyama K., Yokota K., Kagawa S., Shimbara N., Tamura T., Akioka H., Nothwang H. G., Noda C., Tanaka K. and Ichihara A. cDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y. Science 265: 1231-1234, 1994. Ambali A. G. and Jones R. C. The effects of oestrogen and progesterone on re-excretion of infectious bronchitis virus strain G (correction of strainG) in SPF chickens. J Hyg Epidemiol Microbiol Immunol 35: 429-439, 1991. Ariaans M. P., Matthijs M. G., van Haarlem D., van de Haar P., van Eck J. H., Hensen E. J. and Vervelde L. The role of phagocytic cells in enhanced susceptibility of broilers to colibacillosis after Infectious Bronchitis Virus infection. Vet Immunol Immunopathol 123: 240-250, 2008. Arora T., Floyd-Smith G., Espy M. J. and Jelinek D. F. Dissociation between IFN-alpha-induced anti-viral and growth signaling pathways. J Immunol 162: 3289-3297, 1999. Bartlett N. W., Buttigieg K., Kotenko S. V. and Smith G. L. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 86: 1589-1596, 2005. Beaudette F.R. and Hudson C.B. Cultivation of the virus of infectious bronchitis. J Am Vet Med Assoc 90: 51-60, 1937. Behr M., Schieferdecker K., Buhr P., Buter M., Petsophonsakul W., Sirirungsi W., Redmann-Muller I., Muller U., Prempracha N. and Jungwirth C. Interferon-stimulated response element (ISRE)-binding protein complex DRAF1 is activated in Sindbis virus (HR)-infected cells. J Interferon Cytokine Res 21: 981-990, 2001. Beilharz M. W., Cummins J. M. and Bennett A. L. Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem Biophys Res Commun 355: 740-744, 2007. Beilharz M. W., McDonald W., Watson M. W., Heng J., McGeachie J. and Lawson C. M. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J Interferon Cytokine Res 17: 625-630, 1997. Berg R. S., Aggerholm A., Bertelsen L. S., Ostergaard L. and Paludan S. R. Role of mitogen-activated protein kinases, nuclear factor-kappaB, and interferon regulatory factor 3 in Toll-like receptor 4-mediated activation of HIV long terminal repeat. APMIS 117: 124-132, 2009. Bezuidenhout A., Mondal S. P. and Buckles E. L. Histopathological and immunohistochemical study of air sac lesions induced by two strains of infectious bronchitis virus. J Comp Pathol 145: 319-326, 2011. Biron C. A. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr Opin Microbiol 2: 374-381, 1999. Biron C. A. Interferons alpha and beta as immune regulators-a new look. Immunity 14: 661-664, 2001. Biron C. A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 10: 383-390, 1998. Boehm U., Klamp T., Groot M. and Howard J. C. Cellular responses to interferon-gamma. Annu Rev Immunol 15: 749-795, 1997. Bonavita M. S., Franco A., Paroli M., Santilio I., Benvenuto R., De Petrillo G., Levrero M., Perrone A., Balsano C. and Barnaba V. Normalization of depressed natural killer activity after interferon-alpha therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int J Tissue React 15: 11-16, 1993. Bosio E. and Beilharz M. W. Seven days of low-dose orally administered murine type I interferon does not cause priming in vivo. J Interferon Cytokine Res 21: 463-467, 2001. Bosio E., Beilharz M. W., Watson M. W. and Lawson C. M. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo. J Interferon Cytokine Res 19: 869-876, 1999. Boursnell M. E., Brown T. D., Foulds I. J., Green P. F., Tomley F. M. and Binns M. M. Completion of the sequence of the genome of the coronavirus avian infectious bronchitis virus. J Gen Virol 68: 57-77, 1987. Brassard D. L., Grace M. J. and Bordens R. W. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71: 565-581, 2002. Bridle B. W., Julian R., Shewen P. E., Vaillancourt J. P. and Kaushik A. K. T lymphocyte subpopulations diverge in commercially raised chickens. Can J Vet Res 70: 183-190, 2006. Brierley M. M., Marchington K. L., Jurisica I. and Fish E. N. Identification of GAS-dependent interferon-sensitive target genes whose transcription is STAT2-dependent but ISGF3-independent. FEBS J 273: 1569-1581, 2006. Callison S. A., Jackwood M. W. and Hilt D. A. Infectious bronchitis virus S2 gene sequence variability may affect S1 subunit specific antibody binding. Virus Genes 19: 143-151, 1999. Cavanagh D. Coronavirus avian infectious bronchitis virus. Vet Res 38(2): 281-297, 2007. Cavanagh D. Structural characterization of IBV glycoproteins. Adv Exp Med Biol 173: 95-108, 1984. Char D., Sanchez P., Chen C. L., Bucy R. P. and Cooper M. D. A third sublineage of avian T cells can be identified with a T cell receptor-3-specific antibody. J Immunol 145: 3547-3555, 1990. Chehadeh W., Bouzidi A., Alm G., Wattre P. and Hober D. Human antibodies isolated from plasma by affinity chromatography increase the coxsackievirus B4-induced synthesis of interferon-alpha by human peripheral blood mononuclear cells in vitro. J Gen Virol 82: 1899-1907, 2001. Cheng P. N., Jen C. M., Young K. C., Chen C. Y., Lu S. N., Wang C. S. and Chang T. T. High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection-a study in patients with chronic hepatitis C. Hepatogastroenterology 50: 449-452, 2003. Condron R. J. and Marshall A. T. Pathogenesis of infectious bronchitis nephritis. 2. Studies of water and electrolyte balance in colostomised chickens. Avian Pathol 14: 509-520, 1985. Crespo A., Filla M. B., Russell S. W. and Murphy W. J. Indirect induction of suppressor of cytokine signalling-1 in macrophages stimulated with bacterial lipopolysaccharide: partial role of autocrine/paracrine interferon-alpha/beta. Biochem J 349: 99-104, 2000. Cummins J. M., Hutcheson D. P., Cummins M. J., Georgiades J. A. and Richards A. B. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch Immunol Ther Exp (Warsz) 41: 193-197, 1993. Cummins J. M., Mock R. E., Shive B. W., Krakowka S., Richards A. B. and Hutcheson D. P. Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study. Vet Immunol Immunopathol 45: 355-360, 1995. Dansako H., Ikeda M., Ariumi Y., Wakita T. and Kato N. Double-stranded RNA-induced interferon-beta and inflammatory cytokine production modulated by hepatitis C virus serine proteases derived from patients with hepatic diseases. Arch Virol 154: 801-810, 2009. de Weerd N. A., Samarajiwa S. A. and Hertzog P. J. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282(28): 20053-20057, 2007. Dhib-Jalbut S., Jiang H., Xia Q., Blatt L., Johnson K. P. and Hilt D. Comparative effects of interferon-consensus 1, interferon-alpha 2a, and interferon-beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis. J Interferon Cytokine Res 16: 195-200, 1996. Dhinakar Raj G. and Jones R. C. Protectotypic differentiation of avian infectious bronchitis viruses using an in vitro challenge model. Vet Microbiol 53: 239-252, 1996. Dickensheets H. L. and Donnelly R. P. Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons. J Leukoc Biol 65: 307-312, 1999. Doherty P. C. Cytotoxic T cell effector and memory function in viral immunity. Curr Top Microbiol Immunol 206: 1-14, 1996. Dutta T., Spence A. and Lampson L. A. Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains. J Neurooncol 64: 31-44, 2003. Eid P., Meritet J. F., Maury C., Lasfar A., Weill D. and Tovey M. G. Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics. J Interferon Cytokine Res 19: 157-169, 1999. Essayan D. M., Krishnaswamy G., Oriente A., Lichtenstein L. M. and Huang S. K. Differential regulation of antigen-induced IL-4 and IL-13 generation from T lymphocytes by IFN-alpha. J Allergy Clin Immunol 103: 451-457, 1999. Flammer J. R., Dobrovolna J., Kennedy M. A., Chinenov Y., Glass C. K., Ivashkiv L. B. and Rogatsky I. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 30: 4564-4574, 2010. Fleischmann W. R., Jr., Koren S. and Fleischmann C. M. Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc Soc Exp Biol Med 201: 200-207, 1992. Foster G. R. and Finter N. B. Are all type I human interferons equivalent? J Viral Hepat 5: 143-152, 1998. Francis M. L., Fan X. S. and Meltzer M. S. Loss ability to produce IFN-alpha in response to HIV-1 as monocytes differentiate into macrophages. Induction through a mechanism independent of double-stranded RNA. J Immunol 156: 2481-2487, 1996. Fruland J. E., Sandermann S., Snow S. N., Friedl A. and Sharata H. H. Skin necrosis with subsequent formation of squamous cell carcinoma after subcutaneous interferon beta injection. J Am Acad Dermatol 37: 488-489, 1997. Fulton R. M., Reed W. M. and Thacker H. L. Cellular response of the respiratory tract of chickens to infection with Massachusetts 41 and Australian T infectious bronchitis viruses. Avian Dis 37: 951-960, 1993. Galy A., Verma S., Barcena A. and Spits H. Precursors of CD3+CD4+CD8+ cells in the human thymus are defined by expression of CD34. Delineation of early events in human thymic development. J Exp Med 178: 391-401, 1993. Ganapathy K., Cargill P. W. and Jones R. C. A comparison of methods of inducing lachrymation and tear collection in chickens for detection of virus-specific immuoglobulins after infection with infectious bronchitis virus. Avian Pathol 34: 248-251, 2005. Giosue S., Casarini M., Alemanno L., Galluccio G., Mattia P., Pedicelli G., Rebek L., Bisetti A and Ameglio F. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 158: 1156-1162, 1998. Giosue S., Casarini M., Ameglio F., Alemanno L., Saltini C. and Bisetti A. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects. Eur Respir J 9: 42-46, 1996. Godot V., Harraga S., Podoprigora G., Liance M., Bardonnet K. and Vuitton D. A. IFN alpha-2a protects mice against a helminth infection of the liver and modulates immune responses. Gastroenterology 124: 1441-1450, 2003. Gujer C., Sandgren K. J., Douagi I., Adams W. C., Sundling C., Smed-Sorensen A., Seder R. A., Karlsson Hedestam G. B. and Lore K. IFN-alpha produced by human plasmacytoid dendritic cells enhances T cell-dependent naive B cell differentiation. J Leukoc Biol 89: 811-821, 2011. Guo X., Rosa A. J., Chen D. G. and Wang X. Molecular mechanisms of primary and secondary mucosal immunity using avian infectious bronchitis virus as a model system. Vet Immunol Immunopathol 121: 332-343, 2008. Hansson M., Romero A., Thoren F., Hermodsson S. and Hellstrand K. Activation of cytotoxic lymphocytes by interferon-alpha: role of oxygen radical-producing mononuclear phagocytes. J Leukoc Biol 76: 1207-1213, 2004. Harmon B. G. Avian heterophils in inflammation and disease resistance. Poult Sci 77: 972-977, 1998. Holan V., Nakamura S. and Minowada J. Inhibitory versus stimulatory effects of natural human interferon-alpha on proliferation of lymphocyte subpopulations. Immunology 75: 176-181, 1992. Huang Y. P. and Wang C. H. Sequence changes of infectious bronchitis virus isolates in the 3'' 7.3 kb of the genome after attenuating passage in embryonated eggs. Avian Pathol 36: 59-67, 2007. Ignjatovic J. and Galli L. The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens. Arch Virol 138: 117-134, 1994. Ignjatovic J. and Galli U. Immune responses to structural proteins of avian infectious bronchitis virus. Avian Pathol 24: 313-332, 1995. Ignjatovic J. and Sapats S. Avian infectious bronchitis virus. Rev Sci Tech 19: 493-508, 2000. Isaacs A. and Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147: 258-267, 1957. Jackwood M. W., Hilt D. A., Callison S. A., Lee C. W., Plaza H. and Wade E. Spike glycoprotein cleavage recognition site analysis of infectious bronchitis virus. Avian Dis 45: 366-372, 2001. Jarosinski K. W., Jia W., Sekellick M. J., Marcus P. I. and Schat K. A. Cellular responses in chickens treated with IFN-alpha orally or inoculated with recombinant Marek''s disease virus expressing IFN-alpha. J Interferon Cytokine Res 21: 287-296, 2001. Jiang H., Yang H. and Kapczynski D. R. Chicken interferon alpha pretreatment reduces virus replication of pandemic H1N1 and H5N9 avian influenza viruses in lung cell cultures from different avian species. Virol J 8: 447, 2011. Jones R. C. Nephrosis in laying chickens caused by Massachusetts-type infectious bronchitis virus. Vet Rec 95: 319, 1974. Kotani T., Wada S., Tsukamoto Y., Kuwamura M., Yamate J. and Sakuma S. Kinetics of lymphocytic subsets in chicken tracheal lesions infected with infectious bronchitis virus. J Vet Med Sci 62: 397-401, 2000. Kugel D., Kochs G., Obojes K., Roth J., Kobinger G. P., Kobasa D., Haller O., Staeheli P. and von Messling V. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 83: 3843-3851, 2009. Lawson C. M., Yeow W. S., Lee C. M. and Beilharz M. W. In vivo expression of an interferon-alpha gene by intramuscular injection of naked DNA. J Interferon Cytokine Res 17: 255-261, 1997. Lebleu B., Sen G. C., Shaila S., Cabrer B. and Lengyel P. Interferon, double-stranded RNA, and protein phosphorylation. Proc Natl Acad Sci U S A 73: 3107-3111, 1976. Lee C. W., Hilt D. A. and Jackwood M. W. Identification and analysis of the Georgia 98 serotype, a new serotype of infectious bronchitis virus. Avian Dis 45: 164-172, 2001. Lee H. J., Lee Y. N., Youn H. N., Lee D. H., Kwak J. H., Seong B. L., Lee J. B., Park S. Y., Choi I. S. and Song C. S. Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens. Poult Sci 91: 66-73, 2012. Li F., Wang Q. J., Zhu B. L. and Wang M. Antiviral effects of rhIFN-alpha 1 against seven influenza viruses. Zhongguo Yao Li Xue Bao 20: 709-714, 1999. Li Y., Sassano A., Majchrzak B., Deb D. K., Levy D. E., Gaestel M., Nebreda A. R., Fish E. N. and Platanias L. C. Role of p38alpha Map kinase in Type I interferon signaling. J Biol Chem 279: 970-979, 2004. Lin T. L., Loa C. C. and Wu C. C. Existence of gene 5 indicates close genomic relationship of Turkey coronavirus to infectious bronchitis virus. Acta Virol 46: 107-116, 2002. Lin Z., Kato A., Kudou Y., Umeda K. and Ueda S. Typing of recent infectious bronchitis virus isolates causing nephritis in chicken. Arch Virol 120: 145-149, 1991. Lindahl P., Gresser I., Leary P. and Tovey M. Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. Proc Natl Acad Sci U S A 73: 1284-1287, 1976. Liu L., Paul A., MacKenzie C. J., Bryant C., Graham A. and Plevin R. Nuclear factor kappa B is involved in lipopolysaccharide-stimulated induction of interferon regulatory factor-1 and GAS/GAF DNA-binding in human umbilical vein endothelial cells. Br J Pharmacol 134: 1629-1638, 2001. Lombardi D. Method of growth in the chick embryo of the Massachusetts and Connecticut types of avian infectious bronchitis virus. Acta Med Vet (Napoli) 11: 373-379, 1965. Lomniczi B. and Kennedy I. Genome of infectious bronchitis virus. J Virol 24: 99-107, 1977. Lukaszewski R. A. and Brooks T. J. Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J Virol 74: 5006-5015, 2000. MacQuillan G. C., Mamotte C., Reed W. D., Jeffrey G. P. and Allan J. E. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol 70: 219-227, 2003. Makashova V. V. and Florianu A. I. Anti-virus response and interferon, cytokine systems in patients with chronic hepatitis C. Ter Arkh 80: 7-10, 2008. Marcus P. I., van der Heide L. and Sekellick M. J. Interferon action on avian viruses. I. Oral administration of chicken interferon-alpha ameliorates Newcastle disease. J Interferon Cytokine Res 19: 881-885, 1999. Martins N. R., Mockett A. P., Barrett A. D. and Cook J. K. IgM responses in chicken serum to live and inactivated infectious bronchitis virus vaccines. Avian Dis 35: 470-475, 1991. Meseri A., Delwail V., Mahon F. X., Pelletier D., Guilhot F., Brizard A., Gombert J., Tanzer J. and Goube de Laforest P. Natural-killer cell activity and cytogenetic response in chronic myelogenous leukemia treated with alpha-interferon. Br J Haematol 78: 585-586, 1991. Mockett A. P., Cavanagh D. and Brown T. D. Monoclonal antibodies to the S1 spike and membrane proteins of avian infectious bronchitis coronavirus strain Massachusetts M41. J Gen Virol 65: 2281-2286, 1984. Mohty A. M., Grob J. J., Mohty M., Richard M. A., Olive D. and Gaugler B. Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. Immunobiology 215: 113-123, 2010. Moll H. P., Maier T., Zommer A., Lavoie T. and Brostjan C. The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types. Cytokine 53: 52-59, 2011. Moore I., Horney B., Day K., Lofstedt J. and Cribb A. E. Treatment of inflammatory airway disease in young standardbreds with interferon alpha. Can Vet J 45: 594-601, 2004. Mori S., Jewett A., Cavalcanti M., Murakami-Mori K., Nakamura S. and Bonavida B. Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. Int J Oncol 12: 1165-1170, 1998. Nagano Y. and Kojima Y. Immunizing property of vaccinia virus inactivated by ultraviolets rays. C R Seances Soc Biol Fil 148: 1700-1702, 1954. Nagano Y. and Kojima Y. Inhibition of vaccinia infection by a liquid factor in tissues infected by homologous virus. C R Seances Soc Biol Fil 152: 1627-1629, 1958. Nagata S., Mantei N. and Weissmann C. The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha. Nature 287: 401-408, 1980. Nagata S., Taira H., Hall A., Johnsrud L., Streuli M., Ecsodi J., Boll W., Cantell K. and Weissmann C. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284: 316-320, 1980. Nakamura K., Cook J. K., Frazier J. A. and Narita M. Escherichia coli multiplication and lesions in the respiratory tract of chickens inoculated with infectious bronchitis virus and/or E. coli. Avian Dis 36: 881-890, 1992. Naylor P. H., Naylor C. W., Hendrix S. and Leveque F. G. Oral administration of interferon-alpha induces a transient decline in oral mucosal immunoglobulins and an increase in interleukin-5. J Interferon Cytokine Res 19: 953-959, 1999. Neau D., Trimoulet P., Winnock M., Rullier A., Le Bail B., Lacoste D., Ragnaud J. M., Bioulac-Sage P., Lafon M. E., Chene G. and Dupon M. Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 36: 1564-1571, 2003. Niesters H. G., Bleumink-Pluym N. M., Osterhaus A. D., Horzinek M. C. and van der Zeijst B. A. Epitopes on the peplomer protein of infectious bronchitis virus strain M41 as defined by monoclonal antibodies. Virology 161: 511-519, 1987. Nyman T. A., Matikainen S., Sareneva T., Julkunen I. and Kalkkinen N. Proteome analysis reveals ubiquitin-conjugating enzymes to be a new family of interferon-alpha-regulated genes. Eur J Biochem 267: 4011-4019, 2000. Ogawa T., Asai Y., Sakamoto H. and Yasuda K. Oral immunoadjuvant activity of Lactobacillus casei subsp. casei in dextran-fed layer chickens. Br J Nutr 95: 430-434, 2006. Otsuki K., Nakamura T., Kubota N., Kawaoka Y. and Tsubokura M. Comparison of two strains of avian infectious bronchitis virus for their interferon induction, viral growth and development of virus-neutralizing antibody in experimentally-infected chickens. Vet Microbiol 15: 31-40, 1987. Park C. S., Cho J. H., Kang J. M., Kim B. K. and Han M. A. Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP). Auris Nasus Larynx 38: 474-479, 2011. Parr R. L. and Collissor E. W. Epitopes on the spike protein of a nephropathogenic strain of infectious bronchitis virus. Arch Virol 133: 369-383, 1993. Pei J., Sekellick M. J., Marcus P. I., Choi I. S. and Collisson E. W. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. J Interferon Cytokine Res 21: 1071-1077, 2001. Pfeffer L. M., Dinarello C. A., Herberman R. B., Williams B. R., Borden E. C., Bordens R., Walter M. R., Nagabhushan T. L., Trotta P. P. and Pestka S. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58: 2489-2499, 1998. Piccolo G., Franciotta D., Versino M., Alfonsi E., Lombardi M. and Poma G. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment. J Neurol Neurosurg Psychiatry 60: 348, 1996. Puoti M., Rossi S., Forleo M. A., Zaltron S., Spinetti A., Putzolu V., Rodella A. and Carosi G. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J Hepatol 29: 45-52, 1998. Rahman M. M., Uyangaa E., Han Y. W., Kim S. B., Kim J. H., Choi J. Y., Yoo D. J., Hong J. T., Han S. B., Kim B., Kim K. and Eo S. K. Oral administration of live attenuated Salmonella enterica serovar Typhimurium expressing chicken interferon-alpha alleviates clinical signs caused by respiratory infection with avian influenza virus H9N2. Vet Microbiol 154: 140-151, 2011. Raj G. D. and Jones R. C. Immunopathogenesis of infection in SPF chicks and commercial broiler chickens of a variant infectious bronchitis virus of economic importance. Avian Pathol 25: 481-501, 1996. Riber U. and Lind P. Interaction between Salmonella typhimurium and phagocytic cells in pigs. Phagocytosis, oxidative burst and killing in polymorphonuclear leukocytes and monocytes. Vet Immunol Immunopathol 67: 259-270, 1999. Rogge L., Barberis-Maino L., Biffi M., Passini N., Presky D. H., Gubler U. and Sinigaglia F. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185: 825-831, 1997. Rosner D., Stoneman V., Littlewood T., McCarthy N., Figg N., Wang Y., Tellides G. and Bennett M. Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am J Pathol 168: 2054-2063, 2006. Rubinstein M., Rubinstein S., Familletti P. C., Gross M. S., Miller R. S., Waldman A. A. and Pestka S. Human leukocyte interferon purified to homogeneity. Science 202: 1289-1290, 1978. Samuel C. E. Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809, 2001. Sareneva T., Julkunen I. and Matikainen S. IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J Immunol 165: 1933-1938, 2000. Schalk A. F. and Hawn M. C. An apparently new respiratory disease of baby chicks. J Am Vet Med Assoc 78: 413-422, 1931. Schellekens H., Geelen G., Meritet J. F., Maury C. and Tovey M. G. Oromucosal interferon therapy: relationship between antiviral activity and viral load. J Interferon Cytokine Res 21: 575-581, 2001. Schneekloth C., Korfer A., Hadam M., Lopez Hanninen E., Menzel T., Schomburg A., Dallmann I., Kirchner H., Poliwoda H. and Atzpodien J. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo. Acta Haematol 89: 13-21, 1993. Schultze B., Cavanagh D. and Herrler G. Neuraminidase treatment of avian infectious bronchitis coronavirus reveals a hemagglutinating activity that is dependent on sialic acid-containing receptors on erythrocytes. Virology 189: 792-794, 1992. So E. Y., Park H. H. and Lee C. E. IFN-gamma and IFN-alpha posttranscriptionally down-regulate the IL-4-induced IL-4 receptor gene expression. J Immunol 165: 5472-5479, 2000. Spaan W., Cavanagh D. and Horzinek M. C. Coronaviruses: structure and genome expression. J Gen Virol 69: 2939-2952, 1988. Stark G. R., Kerr I. M., Williams B. R., Silverman R. H. and Schreiber R. D. How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998. Steimle V., Siegrist C. A., Mottet A., Lisowska-Grospierre B. and Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265: 106-109, 1994. Suresh M., Karaca K., Foster D. and Sharma J. M. Molecular and functional characterization of turkey interferon. J Virol 69: 8159-8163, 1995. 1. Snyder C. A. and Valle C. D. Lymphocyte proliferation assays as potential biomarkers for exposures. J Toxic Environ Health 34: 127-139, 1991. Taniguchi T., Fujii-Kuriyama Y. and Muramatsu M. Molecular cloning of human interferon cDNA. Proc Natl Acad Sci U S A 77: 4003-4006, 1980. Taylor J. L. and Grossberg S. E. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 25: 23-29, 1998. Tompkins W. A. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 19: 817-828, 1999. Tossing G. Interferon-alpha in treatment of chronic hepatitis C in co-infected HIV-patients in combination with ribavirin and as a pre-load therapy in treatment-naive HIV-positive patients. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (8th ECCATH), 29-31 October, Athens Greece. Eur J Med Res 7: 44-46, 2002. Toth T. E. and Siegel P. B. Cellular defense of the avian respiratory tract: paucity of free-residing macrophages in the normal chicken. Avian Dis 30: 67-75, 1986. Tough D. F., Borrow P. and Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-1950, 1996. Van Roekel H., Clarke M. K., Bullis K. L., Olesiuk O. M. and Sperling F. G. Infectious bronchitis. Am J Vet Res 12: 140-146, 1951. Verra N., Jansen R., Groenewegen G., Mallo H., Kersten M. J., Bex A., Vyth-Dreese F. A., Sein J., van de Kasteele W., Nooijen W. J., de Waal M., Horenblas S. and de Gast G. C. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer 88: 1346-1351, 2003. Vigario A. M., Belnoue E., Gruner A. C., Mauduit M., Kayibanda M., Deschemin J. C., Marussig M., Snounou G., Mazier D., Gresser I. and Renia L. Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice. J Immunol 178: 6416-6425, 2007. Vilcek J. Adverse effects of interferon in virus infections, autoimmune diseases and acquired immunodeficiency. Prog Med Virol 30: 62-77, 1984. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 25: 343-348, 2006. von Hoegen P. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett 47: 157-162, 1995. Wang C. H., Hsieh M. C. and Chang P. C. Isolation, pathogenicity, and H120 protection efficacy of infectious bronchitis viruses isolated in Taiwan. Avian Dis 40: 620-625, 1996. Wang C. H. and Huang Y. C. Relationship between serotypes and genotypes based on the hypervariable region of the S1 gene of infectious bronchitis virus. Arch Virol 145: 291-300, 2000. Wang C. H. and Tsai C. T. Genetic grouping for the isolates of avian infectious bronchitis virus in Taiwan. Arch Virol 141: 1677-1688, 1996. Wang H., Wang Q. H., Wang H. F., Jia J. D., Xie W. and Qin X. Q. A clinical study of the efficacy and safety of secretory human interferon alpha-2a treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 12: 589-592, 2004. Wang X., Rosa A. J., Oliverira H. N., Rosa G. J., Guo X., Travnicek M. and Girshick T. Transcriptome of local innate and adaptive immunity during early phase of infectious bronchitis viral infection. Viral Immunol 19: 768-774, 2006. Weiss R. C., Cummins J. M. and Richards A. B. Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J Am Vet Med Assoc 199: 1477-1481, 1991. Weissenbach J., Chernajovsky Y., Zeevi M., Shulman L., Soreq H., Nir U., Wallach D., Perricaudet M., Tiollais P. and Revel M. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A 77: 7152-7156, 1980. Winterfield R. W. and Hitchner S. B. Etiology of an infectious nephritis-nephrosis syndrome of chickens. Am J Vet Res 23: 1273-1279, 1962. Yoshino S. Effects of oral administration of type I interferon on adjuvant arthritis in rats. Comp Immunol Microbiol Infect Dis 19: 133-138, 1996. Yue S. C., Nowak M., Shaulov-Kask A., Wang R., Yue D., Balk S. P. and Exley M. A. Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo. J Immunol 184: 268-276, 2010. Zheleznikova G. F., Ogurtsov R. P. and Aksenov O. A. Stimulation of antibody formation in mice by endogenous and exogenous interferon. Zh Mikrobiol Epidemiol Immunobiol: 86-91, 1980. Zhou Y., Zhou M., Zhang D., Zhang H. and Zhang L. Immune response of AA broilers to IBV H120 vaccine and sodium new houttuyfonate. Res Vet Sci 89: 373-377, 2010. Zizer E., Bommer M., Barth T. and Dikopoulos N. Severe agranulocytosis as a rare side effect of pegylated interferon therapy for chronic hepatitis B. Z Gastroenterol 49: 596-598, 2011.
摘要: 雞傳染性支氣管炎(Infectious bronchitis, IB)為雞隻重要呼吸道疾病,高發生率及低致死率,死亡主要由二次性細菌感染所引發,造成家禽產業重大經濟損失。本病多以活毒疫苗防疫,但疫苗在各血清型間之交叉保護效力受限制,而肉雞飼養時間短,以抗生素預防二次性感染,又有公共衛生及停藥期之考量。因此,本試驗擬探討口服人類重組干擾素-α (rhIFN-α)對於雞隻免疫之調控,進而評估對抗雞傳染性支氣管炎(Infectious bronchitis virus, IBV)感染的效益。免疫調控試驗選用三週齡商用肉雞,飼料添加不同劑量rhIFN-α (10及1000 IU rhIFN-α/ kg.bw/日),於連續投與3天及7天後進行白血球表現型及功能分析。結果顯示rhIFN-α顯著提升淋巴細胞對分裂原刺激之增殖能力,但對於PBMC中淋巴次族群之改變則有程度不等的調降或調升現象,其中CD8+ T 細胞在1000 IU rhIFN-α連續投與3天後具有正向調升作用。但在吞噬功能及自由基產生方面,則呈輕微負調控現象。IBV感染試驗亦選用商用肉雞,評估對於生長性能及病毒感染的影響,小雞於1週齡時依體重平均分配至4組,分別為10 IU rhIFN-α預防組(A組),於感染前連續一週投予10 IU rhIFN-α/kg.bw/日;10,000 IU rhIFN-α治療組(B組),於感染IBV隔天單次投予10,000 IU rhIFN-α/kg.bw/日;單純IBV感染之陽性對照組(C組);及陰性對照組(D組)。A、B及C組雞隻於2週齡點眼接種IBV (4×105 EID50),並於感染後1週全數犧牲,感染後每日觀察記錄臨床咳嗽指數,以及感染後一週之增重及採食量,評估氣管環纖毛受損情形,以即時定量聚合酶鏈鎖反應檢測肺臟與腎臟的病毒量,本試驗共重複進行3次。結果顯示預防組可改善飼料換肉率,延遲咳嗽發生時間及降低發病嚴重度。而治療組可輕微改善咳嗽症狀,此兩組在於組織病變及臟器之病毒複製量與陽性對照組未有顯著差異。綜合以上結果顯示雞隻口服10 IU rhIFN-α/kg.bw/日可提升淋巴細胞對分裂原刺激之增殖能力及CD8+ T細胞在血液中之相對量,但對吞噬細胞之功能則有負調控現象。口服rhIFN-α對於感染IBV雞隻之生長性能則有輕度提升效益,但對氣管組織傷害及抑制病毒複製則未有顯著影響,這些改變是否與物種間IFN-α交叉調控生物活性不同,投與劑量及投與時間有關,尚待進一步確認。因此,以人類IFN-α在田間作為雞隻之免疫調節劑應用,以對抗家禽病毒感染包括IBV感染之效益,尚待更多評估。
Infectious bronchitis (IB) is one of the important respiratory diseases in chicken characterized by high morbidity and low mortality. The main cause of the death is triggered by secondary bacterial infection leading to the significant economic losses in poultry industry. In spite of the wide use of vaccines, outbreaks of the disease continue to occur in vaccinated flocks, due to less cross-protection of different serotypes. Additionally, broilers are raised in short time to market with considerations of public health and the withdrawal time of drugs, in which it was not right time to use antibiotics for preventing secondary infection. Therefore, the experiment was to investigate the immunoregulation of oral administration of recombinant human interferon-α (rhIFN-α) in chicken and the protective efficiency of rhIFN-α against IBV infection. The immunomodulant test was conducted on three-week-old commercial broilers that were oromucosally administered with different doses of rhIFN-α (10 and 1,000 IU of rhIFN-α/ kg.bw/ day) for 1 week and the lymphocyte phenotype and functional assays were evaluated at day 4 and 8 post treatment. The results indicated that oral administration of rhIFN-α could significantly enhance the lymphocyte proliferative capacity, but cause mild change in lymphoid populations of PBMC, especially in CD8+ subpopulation. In contrast, the phagocytosis and the generation of free radical of phagocytes were negatively regulated. The IBV infection test was conducted in commercial broilers. One week old chickens were body weight matched and randomly divided into 4 groups, rhIFN-α prevention group (10 IU rhIFN-α/ kg.bw/ day), rhIFN-α treatment group (1000 IU rhIFN-α/ kg.bw/ day), positive control group, and negative control group. Chickens were infected with IBV strain TW1 by ocular inoculation at 2 weeks old and sacrificed one week after infection. The clinical score of cough, feed intake and weight gain, tracheal lesion score, and virus loadings of the lung and kidney were evaluated. The infection tests were repeated in three separate trials. These results showed that the preventive treatment of rhIFN-α could slightly improve the feed conversion ratio and decrease the severity of coughing index. In contrast, one therapy treatment after IBV infection using high dosage of 10,000 IU/ kg.bw/ day of rhIFN-α could slightly alter the symptoms of cough and delay the onset of clinical sign. However, the histopathologic lesions of tracheal epithelium and viral loads in lung and kidney of both rhIFN-α treated groups were not significantly different from the positive control group. Taken together, these results suggested that the cross-immunregulation of rhIFN-α on chicken was not obvious as seen in mammalian. Due to less efficiency of cross regulation between human derived IFN and poultry immune system, the duration, times and dosages of administration on poultry need more assessment for further application.
URI: http://hdl.handle.net/11455/15508
其他識別: U0005-1408201218420200
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-1408201218420200
Appears in Collections:獸醫病理生物學所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.